Gland Pharma Ltd
GLANDBSE 543245PharmaceuticalsMkt cap ₹47,418 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹1,800 Cr
YoY +19.6%QoQ +3.3%
Net profit · Q1 FY27
₹317 Cr
YoY +47.1%QoQ -13.6%
Net margin · Q1 FY27
17.6%
+3.3 pts vs Q1 FY26
Net profit · FY26
₹1,027 Cr
YoY +47.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 1,800 | 1,743 | 1,695 | 1,487 | 1,506 | +19.6% |
| Other income | 61.23 | 111 | 63.17 | 84.16 | 57.53 | +6.4% |
| Total income | 1,862 | 1,854 | 1,759 | 1,571 | 1,563 | +19.1% |
| Profit before tax | 435 | 506 | 362 | 284 | 313 | +39.1% |
| Tax | 118 | 139 | 101 | 100 | 97.26 | +21.3% |
| Net profit | 317 | 367 | 261 | 184 | 215 | +47.1% |
| Net margin | 17.6% | 21.0% | 15.4% | 12.3% | 14.3% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 6,431 | 5,617 | 5,665 | 3,625 | 4,401 | +14.5% |
| Other income | 316 | 214 | 170 | 240 | 224 | +48.1% |
| Total income | 6,747 | 5,830 | 5,835 | 3,865 | 4,625 | +15.7% |
| Profit before tax | 1,465 | 1,063 | 1,133 | 1,055 | 1,619 | +37.8% |
| Tax | 437 | 364 | 360 | 274 | 407 | +20.1% |
| Net profit | 1,027 | 699 | 772 | 781 | 1,212 | +47.1% |
| Net margin | 16.0% | 12.4% | 13.6% | 21.6% | 27.5% |
BIC's take
We haven't covered Gland Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:38 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.